Neymeyr patent opposition analysis

The comprehensive analysis of Neymeyr opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Stay updated with the latest patent oppositions filed by Neymeyr

Patent NumberTitleApplicantOpposition DateOpposition Company
Compositions And Methods For Treating Disorders Ameliorated By Muscarnic Receptor ActivationKARUNA THERAPEUTICS, INC.Sep 24, 2026DR. SCHÖN, NEYMEYR & PARTNER PATENTANWÄLTE MBB
Method And Device For Estimating The Condition Of An Electrical NetworkSIEMENS AKTIENGESELLSCHAFTJun 24, 2026DR. SCHÖN, NEYMEYR & PARTNER PATENTANWÄLTE MBB
Formulations Of Ag10EIDOS THERAPEUTICS, INC.Jun 23, 2026DR. SCHÖN, NEYMEYR & PARTNER PATENTANWÄLTE MBB
Method Of Synthesizing Thyroid Hormone Analogs And Polymorphs ThereofMADRIGAL PHARMACEUTICALS, INC.Jun 9, 2026DR. SCHÖN, NEYMEYR & PARTNER PATENTANWÄLTE MBB
New Use Of A Combination Of Sacubitril And ValsartanNOVARTIS AGFeb 12, 2026DR. SCHÖN, NEYMEYR & PARTNER PATENTANWÄLTE MBB
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTIS AGJan 29, 2026DR. SCHNEIDER KUNSTSTOFFWERKE GMBH
Manufacture Of A Crystalline Pharmaceutical ProductORION CORPORATIONJan 9, 2026DR. SCHNEIDER KUNSTSTOFFWERKE GMBH
Crystal Form Of Ozanimod, Crystal Form Of Hydrochloride Thereof, And Preparation Method ThereforRECEPTOS LLCDec 23, 2025DR. SCHNEIDER KUNSTSTOFFWERKE GMBH
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTIS AGJul 16, 2025DR. SCHÖN, NEYMEYR & PARTNER PATENTANWÄLTE MBB
Methods For Dose Initiation Of Aripiprazole TreatmentsOTSUKA PHARMACEUTICAL CO., LTD.Jul 1, 2025DR. SCHNEIDER KUNSTSTOFFWERKE GMBH